Synonyms: compound 1 [PMID: 30044619] | Evrysdi® | RG-7916 | RG7916 | RO-7034067 | RO7034067
risdiplam is an approved drug (FDA (2020), EMA (2021))
Compound class:
Synthetic organic
Comment: Risdiplam is a first-in-class, orally bioavailable splicing modifier [3]. Like nusinersen, it is intended to improve the efficiency of SMN2 (HGNC ID 11118; Uniprot Q16637) gene transcription in patients with spinal muscular atrophy (SMA) [2].
|
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2020), EMA (2021)) |
International Nonproprietary Names | |
INN number | INN |
10614 | risdiplam |
Synonyms |
compound 1 [PMID: 30044619] | Evrysdi® | RG-7916 | RG7916 | RO-7034067 | RO7034067 |
Database Links | |
ChEMBL Ligand | CHEMBL4297528 |
DrugBank Ligand | DB15305 |
DrugCentral Ligand | 5407 |
GtoPdb PubChem SID | 434122230 |
PubChem CID | 118513932 |
Search Google for chemical match using the InChIKey | ASKZRYGFUPSJPN-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | ASKZRYGFUPSJPN |
Search PubMed clinical trials | risdiplam |
Search PubMed titles | risdiplam |
Search PubMed titles/abstracts | risdiplam |
UniChem Compound Search for chemical match using the InChIKey | ASKZRYGFUPSJPN-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | ASKZRYGFUPSJPN-UHFFFAOYSA-N |